Skip to content

Monopar Therapeutics

US · MNPR #3671 by market cap Listed 2019
69.00 -1.29 -1.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 69.00 -1.84%
After-hours 67.35 -2.40%
123.8459.1069.002026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MNPR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -27.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 16.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Return on equity -14.2% Better than 18%
Return on invested capital -17.3% Better than 14%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -35.9% Better than 13%
6-month return 9.3% Better than 71%
12-month return (ex latest month) -22.8% Better than 13%
Distance below 52-week high 44.7% Better than 24%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 51.4x Better than 100%
Debt to assets 0.1% Better than 98%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 86.5% Better than 80%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.17%
1M -7.05%
3M -37.77%
6M +6.24%
YTD +5.67%
1Y -16.87%
3Y +4,675.09%
5Y +192.99%

Key statistics

Price & volume

Prev close
70.29
Open
68.50
Day range
67.36 - 69.86
Avg price
68.44
Volume
132.64K
Turnover
9.08M
Amplitude
3.56%
52-week range
50.07 - 124.82

Valuation

P/E
-37.30
P/E (TTM)
-28.28
P/B
3.68
EPS
-1.85
Net profit
-12.54M
Net assets
127.06M

Share structure

Market cap
467.60M
Float cap
312.74M
Shares out
6.78M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-12-19
52-week range 25% of range
50.07 124.82

44.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-144.54K net over the window

Short interest

Shares short
1.10M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Monopar Therapeutics (MNPR)?

Monopar Therapeutics last traded at 69.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Monopar Therapeutics's market cap?

About 467.60M.

What is the P/E ratio of Monopar Therapeutics?

The trailing twelve-month P/E is -28.28. The Valuation tab shows it against the stock's own five-year range.

Does Monopar Therapeutics pay a dividend?

Monopar Therapeutics does not currently pay a regular dividend.

Is Monopar Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 128.67, which implies 86.5% upside from the current price. This is not investment advice.

What is Monopar Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Monopar Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Monopar Therapeutics discussion 0 comments

Add a comment